Nasdaq Issues Delisting Determination to Agape ATP Corp for Low Stock Price

summarizeSummary

Agape ATP Corp received a formal delisting determination from Nasdaq due to its failure to meet the minimum bid price and low-priced stock rules, though it plans to appeal.

check_boxKey Events · Corporate Governance and Compliance · ATPC

• Nasdaq Delisting Determination Issued

  Agape ATP Corp received an additional notification from Nasdaq on February 2, 2026, stating that Nasdaq Staff has determined to delist the company's securities. This determination is based on the company's common stock having a closing bid price of $0.10 or less for ten consecutive trading days as of January 30, 2026, violating Nasdaq Listing Rule 5810(c)(3)(A)(iii), the 'Low Priced Stocks' Rule.

• Follows Prior Non-Compliance Notice

  This delisting determination follows a previous notification on January 29, 2026, regarding the company's non-compliance with Nasdaq's minimum $1.00 bid price requirement (Rule 5550(a)(2)).

• Company Plans to Appeal

  Agape ATP Corp has until February 9, 2026, to request a hearing with the Nasdaq Hearings Panel. The company intends to make this request, which will stay the suspension of its securities and the filing of Form 25-NSE pending the Panel's decision.

• Context of Recent Corporate Actions

  This delisting notice comes shortly after shareholders approved a highly dilutive $300 million stock offering and an extreme 1:5000 reverse stock split on February 2, 2026, highlighting significant ongoing corporate challenges.

auto_awesomeAnalysis · ATPC · Industrial Applications And Services

Agape ATP Corp has received a formal delisting determination from Nasdaq, escalating its compliance issues. This follows a prior notification for failing to maintain the minimum $1.00 bid price and is now based on the 'Low Priced Stocks' rule, where the stock traded at $0.10 or less for ten consecutive days. While the company intends to appeal, the determination itself is a severe negative signal, indicating a high probability of moving to an over-the-counter market, which typically results in reduced liquidity and investor interest. This development adds to the significant challenges the company faces, coming shortly after shareholders approved a highly dilutive $300 million stock offering and an extreme 1:5000 reverse stock split, suggesting a precarious financial and operational position.